Passage BIO (PASG) Share-based Compensation (2019 - 2026)
Passage BIO (PASG) posted quarterly Share-based Compensation of $556000.0 for Q1 2026, down 35.2% year-over-year from $858000.0 in Q1 2025, and down 8.7% quarter-over-quarter from $609000.0 in Q4 2025.
Passage BIO (PASG) Share-based Compensation (2019 - 2026) Analysis & Trends
Passage BIO's Share-based Compensation history runs 8 years deep, the most recent figure standing at $556000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 35.2% year-over-year to $556000.0; the TTM figure through Mar 2026 stood at $2.7 million (up 245.26% YoY), while the FY2025 annual figure was $3.0 million, down 47.35% from the prior year.
- Share-based Compensation for Q1 2026 stood at $556000.0, down from $609000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $6.3 million in Q1 2022, with the low at -$4.2 million in Q4 2024.
- The 5-year median for Share-based Compensation is $1.6 million (2023), against an average of $1.9 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation surged 4729.17% in 2022, then slumped 364.39% in 2024.
- Passage BIO's Share-based Compensation stood at $3.5 million in 2022, then tumbled by 54.85% to $1.6 million in 2023, then plunged by 364.39% to -$4.2 million in 2024, then jumped by 114.67% to $609000.0 in 2025, then decreased by 8.7% to $556000.0 in 2026.
- Business Quant data shows PASG's Share-based Compensation at $556000.0 in Q1 2026, $609000.0 in Q4 2025, and $611000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Jun 30, 2026 | 1.60 Mn |
| Mar 31, 2026 | 556,000.00 |
| Mar 31, 2026 | 556,000.00 |
| Dec 31, 2025 | 609,000.00 |
| Dec 31, 2025 | 609,000.00 |
| Sep 30, 2025 | 611,000.00 |
| Sep 30, 2025 | 611,000.00 |
| Jun 30, 2025 | 923,000.00 |
| Jun 30, 2025 | 923,000.00 |
| Mar 31, 2025 | 858,000.00 |
| Mar 31, 2025 | 858,000.00 |
| Dec 31, 2024 | -4.15 Mn |
| Dec 31, 2024 | -4.15 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 1.60 Mn |
| Mar 31, 2024 | 1.60 Mn |